利拉格卢提德通过抑制NF-κb酸化和减少表皮-介质细胞过渡来改善子宫内粘附

相关实验视频

Updated: Sep 12, 2025

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development

Published on: June 24, 2020

Jie Shi¹, Weicong Xu¹, Tao Yang²

¹Department of Gynecology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Experimental cell research

|August 10, 2025

概括

作为GLP-1受体激动剂的利拉格卢提德通过向NF-κb,在子宫内粘附模型中有效降低子宫炎症和纤维化,为女性生殖功能障碍提供了潜在的新疗法.

科学领域:

生殖医学生殖医学
内分泌学在内分泌学.
细胞生物学细胞生物学

背景情况:

宫内粘附 (IUA) 损害女性生殖功能,治疗选择有限.
像Semaglutide和Dulaglutide这样的GLP-1受体激动剂在缓解IUA方面表现有前途.
另一种GLP-1激动剂利拉格卢提德在IUA治疗中的潜力仍然未被探索.

研究的目的:

调查利拉格卢提德对子宫内粘附 (IUA) 的保护作用.
在IUA模型中阐明liraglutide作用的潜在分子机制.

主要方法:

已建立的IUA老鼠模型和人类子宫内膜器官器官模型.
使用组织学染色 (H&E,Masson) 评估炎症和纤维化.
通过免疫组织化学,免疫光和西部斑块量化E-cadherin和N-cadherin;使用SuperPred和CETSA分析了NF-κb相互作用.

主要成果:

在大鼠和人类有机体IUA模型中,利拉格卢提德治疗降低了子宫内膜炎症,原纤维化和上皮-介质细胞过渡 (EMT).
在IUA中升高的NF-κb酸化被liraglutide逆转.
利拉格卢提德直接准NF-κb,干扰这种相互作用减弱了利拉格卢提德的治疗作用.

结论:

利拉格卢提德通过直接准NF-κb来改善IUA.
利拉格卢提德抑制NF-κb酸化可以减少EMT,炎症和纤维化.
利拉格卢提德为改善子宫内粘附和女性生殖健康提供了一个有前途的治疗策略.

关键词:

皮质 - 介质细胞过渡.宫内粘附在子宫内粘附.利拉格卢提德 (Liraglutide) 是一种类药物.这就是NF-κbb.

更多相关视频

Author Spotlight: Advancing Therapeutic Strategies for Improving Pregnancy Rates by Analyzing Embryo-Endometrium Interactions

Author Spotlight: Advancing Therapeutic Strategies for Improving Pregnancy Rates by Analyzing Embryo-Endometrium Interactions

Published on: June 21, 2024

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Transcytosis of IgG

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...

Intracellular Signaling Affects Focal Adhesions

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...